PROCLAIMING MAY 2026 AS "CYSTIC FIBROSIS AWARENESS MONTH" IN THE STATE OF DELAWARE.

Legislation Document

SPONSOR:

Sen. Hocker & Rep. Jones Giltner

Sens. Buckson, Hansen, Hoffner, Huxtable, Lawson, Mantzavinos, Pettyjohn, Pinkney, Sokola, Wilson; Reps. Berry, Bolden, Bush, Carson, Dukes, Gorman, Morrison, Snyder-Hall, Yearick

DELAWARE STATE SENATE

153rd GENERAL ASSEMBLY

SENATE CONCURRENT RESOLUTION NO. 186

PROCLAIMING MAY 2026 AS "CYSTIC FIBROSIS AWARENESS MONTH" IN THE STATE OF DELAWARE.

WHEREAS, cystic fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 40,000 children and adults in the United States and over 70,000 worldwide; and

WHEREAS, an estimated 105,000 people are diagnosed with cystic fibrosis across 94 countries; and

WHEREAS, more than 75% of patients are diagnosed by age two; and

WHEREAS, in the 1950s, few children with cystic fibrosis lived to attend elementary school; and

WHEREAS, today, because of improved medical treatments and care, more than half of people with cystic fibrosis are 18 years and older, and many people now live healthy, fulfilling lives into their 30s, 40s, and beyond; and

WHEREAS, according to the 2024 Cystic Fibrosis Foundation highlights, based on 2023 CF Foundation Patient Registry data, the median life expectancy of people with CF who are born between 2020 and 2024 is predicted to be 65 years; and

WHEREAS, advancements in research and medical treatments have further enhanced and extended the lives of children and adults with cystic fibrosis; and

WHEREAS, through the drug development pipeline of the Cystic Fibrosis Foundation, significant progress has been achieved in the search for new treatments, and a cure for this disease is being developed; and

WHEREAS, in 2018, the FDA approved the use of lumacaftor/ivacaftor for children with cystic fibrosis up to 24 months of age, which allowed about 1,300 additional children in the U.S. to be eligible to receive the drug, bringing the total number of those in the U.S. who could benefit from the treatment to approximately 12,300; and

WHEREAS, the FDA approved Trikafta, the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation in 2019; and

WHEREAS, significant progress has been observed in achieving a long-term cure through genetic therapy; and

WHEREAS, continuous promotion of support and awareness of Cystic Fibrosis can help positively affect tens of thousands of Americans.

NOW, THEREFORE:

BE IT RESOLVED by the Senate of the 153rd General Assembly of the State of Delaware, the House of Representatives concurring therein, that May 2026 is hereby proclaimed “Cystic Fibrosis Awareness Month” in the State of Delaware.

BE IT FURTHER RESOLVED that a suitably prepared copy of this resolution be presented to the Cystic Fibrosis Foundation.

SYNOPSIS

This Senate Concurrent Resolution proclaims May 2026 "Cystic Fibrosis Awareness Month" in the State of Delaware.

Author: Senator Hocker